Pfizer PFE Goldman Sachs Healthcare Conference Transcript
- Pfizer's CEO, Albert Bourla, addressed the Goldman Sachs 46th Annual Global Healthcare Conference, engaging in a discussion about the pharmaceutical industry's external environment and drug pricing policy.
- Asad Haider, from Goldman sachs, initiated the conversation by acknowledging the widespread investor concerns about pharmaceutical industry outlook.
- Albert Bourla said, "Apparently, there is a lot of anxiety with investors, which is very obvious in the multiples of all the pharma that have been depressed."
Pfizer CEO Albert Bourla tackled investor anxieties head-on at the Goldman Sachs Healthcare Conference, specifically addressing the complexities surrounding drug pricing policy. Bourla, also the Chairman, provided crucial insights into ongoing dialogues in Washington, D.C., particularly those around the Most favored Nation (MFN) executive order. news Directory 3 brings you this essential breakdown of how Bourla navigated concerns within the pharmaceutical industry outlook and the potential impact on market multiples. Investors are keen to understand the current state of affairs and anticipate short- and long-term implications. Discover what’s next as the industry adapts to evolving regulations.
Pfizer CEO Discusses Drug Pricing Policy at healthcare Conference
Updated June 9, 2025
Pfizer’s CEO, Albert Bourla, addressed the Goldman Sachs 46th Annual Global Healthcare Conference, engaging in a discussion about the pharmaceutical industry’s external environment and drug pricing policy. Bourla, also the Chairman of a pharma lobbying group, offered insights into ongoing conversations in Washington, D.C., notably concerning the Most Favored Nation (MFN) executive order. The discussion highlighted investor anxiety and its impact on pharma multiples.
Asad Haider, from Goldman sachs, initiated the conversation by acknowledging the widespread investor concerns about pharmaceutical industry outlook. He noted bourla’s unique perspective, given his role and access to policy discussions. Haider inquired about the current state of affairs regarding the MFN executive order and what the industry anticipates in both the short and long term.
Albert Bourla said, “Apparently, there is a lot of anxiety with investors, which is very obvious in the multiples of all the pharma that have been depressed.”
What’s next
The pharmaceutical industry continues to monitor policy developments and adapt strategies in response to evolving regulations and market dynamics, focusing on maintaining innovation and patient access to medications.